Journal Article Summary
The article examines the efficacy of a once-daily inhaled medication, fluticasone furoate/vilanterol (FF/VI), compared to twice-daily combination therapies for asthma management. This topic is significant because asthma affects millions of people worldwide, and effective management is crucial for improving patients' quality of life and reducing exacerbations. FF/VI has been approved in Europe as a maintenance therapy for persistent asthma, and understanding its effectiveness relative to established treatments can help guide treatment choices for patients.
The researchers conducted a mixed treatment comparison analysis using data from 31 randomized controlled trials involving patients aged 12 and older with asthma. They focused on four key outcomes: lung function (measured by peak expiratory flow and forced expiratory volume), exacerbation rates, and health status as assessed by the Asthma Quality of Life Questionnaire. The findings indicated that both doses of FF/VI were likely non-inferior to the corresponding doses of established twice-daily therapies, fluticasone propionate/salmeterol and budesonide/formoterol, in terms of lung function and health status. However, the results regarding exacerbation rates were inconclusive due to insufficient data.
Despite the promising results, the study has limitations, including variability across the included trials and a lack of data on exacerbation rates for one of the FF/VI doses. Patients should be aware that while the analysis supports the efficacy of FF/VI, real-world effectiveness may vary. It is essential for patients to discuss their treatment options with healthcare professionals, considering individual circumstances and preferences, to ensure the best management of their asthma.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Svedsater Henrik, Stynes Gillian, Wex Jaro, Frith Lucy, Leather David, Castelnuovo Emanuela, Detry Michelle, Berry Scott. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy. Asthma research and practice 2016. DOI: 10.1186/s40733-015-0016-0. PMID: 27965772. PMCID: PMC5142397.
Featured Pill Pals Product
Fluticasone Propionate 50 mcg Nasal Spray --- Generic for Flonase --- Apotex Pharma
Fluticasone Propionate 50 mcg Nasal Spray — Generic for Flonase — Apotex Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
